共 50 条
- [21] Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2013, 33 (06): : 414 - 421
- [25] Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (04) : 482 - 489
- [27] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2014, 63 (37): : 822 - 825
- [28] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2019, 68 (46): : 1069 - 1075
- [29] Pneumococcal Conjugate Vaccine-elicited Antibody Persistence and Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Children Previously Vaccinated with 4 Doses of Either 7-Valent or 13-Valent Pneumococcal Conjugate Vaccine PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (10) : 1065 - 1076